Fritextsökning
Artiklar per år
Innehållstyper
-
The pandemic caused a reshuffle among the world’s vaccine giants – here is the new top list
Fuelled by the pandemic, the power balance in the global vaccine market has completely changed in recent years, a survey from Fierce Pharma shows
-
Promising Alzheimer’s study data sends Bioarctic stock soaring
The drug candidate lecanemab from Swedish company Bioarctic significantly slowed down the deterioration in patients with early on-set Alzheimer’s, according to preliminary results from a phase III study.
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward
-
Konferens om läkemedelsformuleringar samlar branschen i Köpenhamn
Idag pågår den tionde upplagan av New Updates in Drug Formulation & Bioavailability 2022 i Köpenhamn.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?
Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
-
Björn Ursing: Physicians new role in AI driven healthcare
”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians changes in the era of AI.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
-
Life Science Sweden´s international issue is on its way
A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.
-
Patient som fick grishjärta återhämtar sig – inga tecken på avstötning
Den amerikanske man som fick ett genmodifierat grishjärta transplanterat i början av året återhämtar sig fortfarande på sjukhus. Efter fem veckor syns inga tecken på avstötning, enligt läkare.
-
Stockholm aims at becoming one of the world’s top life science regions
Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 2025. One step on the way to achieve this is by hosting a world-leading congress in medtech.
-
Anna Törner: Success requires bold decisions!
“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.
-
Lockdown-studie kritiseras även i USA
I USA har den uppmärksammade metastudie som uppger att knappt några liv har räddats med hjälp av lockdowns blivit kraftigt ifrågasatt av forskare.
-
Första bekräftade dödsfallet i omikron i Storbritannien
Minst en person har dött i omikronvarianten i Storbritannien. Det uppger premiärminister Boris Johnson.
-
Genterapier och vaccin dryftas på branschmötet
-
WHO rekommenderar det första malariavaccinet för barn: "En historisk dag"
Världshälsoorganisationen WHO rekommenderar en storskalig användning av världens första malariavaccin.
-
Uppgifter: Amerikanskt företag vill förvärva Sobi
Det amerikanska riskkapitalbolaget Advent International överväger att lägga ett bud på svenska Sobi, enligt uppgifter.
-
Hallå där Korbinian Löbmann
Korbinian Löbmann kommer att moderera Life Science Swedens kommande event New updates in Drug Formulation & Bioavailability den 1 september.
-
Här är virusvarianterna du ska ha koll på
Glöm den brittiska, sydafrikanska och indiska varianten. Efter att flera länder klagat beslutade WHO om nya namn på olika muterade coronavirus.
-
Petter Hartman: Prioritera kommunikationen om forskning!
Vad fan får jag för pengarna? Forskning bör vara ett svar på den frågan, anser Petter Hartman.
-
Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system
Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior Consultant at RegSmart Life Science, develops her views on this subject.
-
Vaccinforskare om danska stoppet: "Ingen visad koppling till proppar"
Sverige fortsätter att vaccinera med Astra Zenecas covidvaccin när flera andra länder pausar distributionen efter uppgifter om möjliga allvarliga biverkningar. Och Sverige gör rätt, menar vaccinforskaren Ali Harandi.